Arizona Liver Health

Chandler, Arizona 85712

7 studies enrolling now · 27 studies all time

What they study most

Ascites Hepatic, COVID-19, Chronic Hepatitis b, Chronic Liver Disease, Cirrhosis, Liver, Compensated Cirrhosis, Fatty Liver, Healthy, Hepatic Impairment, Liver Diseases, Liver Fibrosis, MASLD

Studies at this site

• A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) — Recruiting now
• A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis — Recruiting now
• A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) — Recruiting now
• A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition — Recruiting now
• Non-Invasive Quantification of Liver Health in NASH (N-QUAN) — Recruiting now
• Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics — Recruiting now
• DELIVER Study in a Population With Clinical Suspicion of Liver Cirrhosis — Completed
• A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension — Completed
• A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants — Completed
• An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) — Completed
• Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection — Completed
• Assessment of Non-Invasive Testing in Major Liver-Related Outcomes — Enrolling by invitation
• A POC and Dose-Ranging Study of HTD1801 in PSC Patients — Completed
• A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4 — Stopped early
• A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis. — Completed
• The SHUNT-V Study for Varices — Completed
• A Phase 2b Study of Icosabutate in Fatty Liver Disease — Completed
• A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906 — Completed
• A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage — Completed
• Effects of Online App Weight Loss Programs on Liver Health in Obese Adults — Completed
• Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis — Completed
• Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis — Stopped early
• Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD) — Completed
• A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH — Stopped early
• Nutritional Cognitive Behavioral Therapy Feasibility Study in NAFLD and NASH — Completed
• Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) — Completed
• Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting — Stopped early